NEW YORK (GenomeWeb News) – GenMark Diagnostics reported after the close of the market on Tuesday that its revenues in the fourth quarter fell 31 percent year over year, but the company still beat the average Wall Street estimate on the top and bottom lines.

The Carlsbad, Calif.-based molecular diagnostics firm reported $6.5 million in total revenues for the three months ended Dec. 31, 2013, compared to $9.4 million in the year-ago fourth quarter and besting the consensus Wall Street estimate of $6.1 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: the Human Silencing Hub protein complex, and more.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.